Translating science
into innovative
diagnostic solutions

Quadrant news

Latest news

Clarifi COVID-19 Testing

Quadrant Biosciences has received an Emergency Use Authorization (EUA) from the FDA for the Clarifi COVID-19 Test Kit by SUNY Upstate Medical and Quadrant Biosciences, a saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.

Click on the link to read the full press release:

Quadrant Receives NIH Grant for TBI Study

Quadrant Biosciences has received a $2.3 million grant from the National Institutes of Health to develop its saliva-based microRNA diagnostic test for concussions in children and adolescents. (The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.)

Click on the link to read the full press release:

Our aim is to develop solutions for important global health issues

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary  advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI,  through the application of the Clarifi®  epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. Clarifi ASD, an autism diagnostic aid, is the first product to launch commercially from this platform. Clarifi ASD is now available through prescription; details on how to obtain testing are available on Clarifi’s website


Finally, we are involved in three significant, complementary COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.

Development, Solutions, Global Health Issues, Groundbreaking
Quadrant Biosciences, biotech, Development, Global Health Issues, Solutions, Diagnostic, Early Detection
Quadrant Biosciences, Development, Global Health Issues, Solutions, Diagnostic, Early Detection

Be part of a study

Be part of a study

Autism research study

Children ages 18 months to 48 months with an autism diagnosis, developmental delays, or a suspicion of autism are eligible.

Parkinson’s Study

Help us learn how to better diagnose Parkinson’s Disease at an earlier stage.